25 XP   0   0   10

Maxigen Biotech Inc
Buy, Hold or Sell?

Let's analyse Maxigen Biotech Inc together

PenkeI guess you are interested in Maxigen Biotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Maxigen Biotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Maxigen Biotech Inc

I send you an email if I find something interesting about Maxigen Biotech Inc.

Quick analysis of Maxigen Biotech Inc (30 sec.)










What can you expect buying and holding a share of Maxigen Biotech Inc? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
56.5%

What is your share worth?

Current worth
NT$15.30
Expected worth in 1 year
NT$16.04
How sure are you?
87.0%

+ What do you gain per year?

Total Gains per Share
NT$0.74
Return On Investment
1.6%

For what price can you sell your share?

Current Price per Share
NT$45.70
Expected price per share
NT$44.30 - NT$50.00
How sure are you?
50%

1. Valuation of Maxigen Biotech Inc (5 min.)




Live pricePrice per Share (EOD)

NT$45.70

Intrinsic Value Per Share

NT$6.49 - NT$6.99

Total Value Per Share

NT$21.80 - NT$22.29

2. Growth of Maxigen Biotech Inc (5 min.)




Is Maxigen Biotech Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$42.6m$38.4m$3.7m8.8%

How much money is Maxigen Biotech Inc making?

Current yearPrevious yearGrowGrow %
Making money$1.2m$1m$206.7k15.9%
Net Profit Margin26.3%22.7%--

How much money comes from the company's main activities?

3. Financial Health of Maxigen Biotech Inc (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#125 / 173

Most Revenue
#135 / 173

Most Profit
#96 / 173

What can you expect buying and holding a share of Maxigen Biotech Inc? (5 min.)

Welcome investor! Maxigen Biotech Inc's management wants to use your money to grow the business. In return you get a share of Maxigen Biotech Inc.

What can you expect buying and holding a share of Maxigen Biotech Inc?

First you should know what it really means to hold a share of Maxigen Biotech Inc. And how you can make/lose money.

Speculation

The Price per Share of Maxigen Biotech Inc is NT$45.70. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Maxigen Biotech Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Maxigen Biotech Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$15.30. Based on the TTM, the Book Value Change Per Share is NT$0.18 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.43 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Maxigen Biotech Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.010.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Book Value Change Per Share0.000.0%0.010.0%0.010.0%0.010.0%0.020.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.000.0%0.010.0%0.010.0%0.010.0%0.030.1%
Usd Price Per Share1.51-1.76-1.41-1.21-1.17-
Price to Earnings Ratio60.92-35.56-26.65-39.71-40.47-
Price-to-Total Gains Ratio-534.31--135.44-111.26-44.35-42.93-
Price to Book Ratio3.16-3.72-3.26-3.18-3.14-
Price-to-Total Gains Ratio-534.31--135.44-111.26-44.35-42.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.43041
Number of shares699
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.010.01
Usd Total Gains Per Share0.010.01
Gains per Quarter (699 shares)4.0310.43
Gains per Year (699 shares)16.1041.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10166271532
203222533074
3048388045116
40645410760158
50817013475200
60978616090242
70113102187105284
80129118214120326
90145134241135368
100161150267150410

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%23.00.00.0100.0%23.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%10.02.00.083.3%15.05.00.075.0%18.05.00.078.3%18.05.00.078.3%
Dividend per Share0.00.04.00.0%3.00.09.025.0%10.00.010.050.0%13.00.010.056.5%13.00.010.056.5%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%17.03.00.085.0%20.03.00.087.0%20.03.00.087.0%

Fundamentals of Maxigen Biotech Inc

About Maxigen Biotech Inc

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; and BestAid, a collagen bone graft. It also provides FormaAid, a guided tissue regeneration membrane; HealiAid, a collagen wound dressing product for dental and surgical use; PreviscAid, an ophthalmic viscoelastic device; BiVisc, an ophthalmic viscoelastic system; ViscAid, an ophthalmic viscoelastic device; and dermal filler injections under the Formaderm brand. In addition, the company engages in the manufacturing and sales of beauty care products. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.

Fundamental data was last updated by Penke on 2024-03-25 11:31:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Maxigen Biotech Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Maxigen Biotech Inc earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of 11.9% means that NT$0.12 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Maxigen Biotech Inc:

  • The MRQ is 11.9%. The company is making a huge profit. +2
  • The TTM is 26.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ11.9%TTM26.3%-14.5%
TTM26.3%YOY22.7%+3.7%
TTM26.3%5Y18.5%+7.8%
5Y18.5%10Y18.0%+0.5%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9%6.2%+5.7%
TTM26.3%7.4%+18.9%
YOY22.7%8.0%+14.7%
5Y18.5%7.1%+11.4%
10Y18.0%7.7%+10.3%
1.1.2. Return on Assets

Shows how efficient Maxigen Biotech Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • 1.2% Return on Assets means that Maxigen Biotech Inc generated NT$0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Maxigen Biotech Inc:

  • The MRQ is 1.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.2%TTM2.7%-1.6%
TTM2.7%YOY2.6%+0.2%
TTM2.7%5Y2.0%+0.7%
5Y2.0%10Y2.0%+0.1%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2%1.2%0.0%
TTM2.7%1.2%+1.5%
YOY2.6%1.7%+0.9%
5Y2.0%1.6%+0.4%
10Y2.0%1.6%+0.4%
1.1.3. Return on Equity

Shows how efficient Maxigen Biotech Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • 1.3% Return on Equity means Maxigen Biotech Inc generated NT$0.01 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Maxigen Biotech Inc:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM3.1%-1.8%
TTM3.1%YOY2.8%+0.3%
TTM3.1%5Y2.4%+0.7%
5Y2.4%10Y2.3%+0.0%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%2.3%-1.0%
TTM3.1%2.6%+0.5%
YOY2.8%3.1%-0.3%
5Y2.4%3.2%-0.8%
10Y2.3%3.0%-0.7%

1.2. Operating Efficiency of Maxigen Biotech Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Maxigen Biotech Inc is operating .

  • Measures how much profit Maxigen Biotech Inc makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Maxigen Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY17.9%-17.9%
TTM-5Y15.0%-15.0%
5Y15.0%10Y14.5%+0.6%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.4%-8.4%
TTM-6.5%-6.5%
YOY17.9%10.7%+7.2%
5Y15.0%10.1%+4.9%
10Y14.5%8.4%+6.1%
1.2.2. Operating Ratio

Measures how efficient Maxigen Biotech Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.08 means that the operating costs are NT$1.08 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Maxigen Biotech Inc:

  • The MRQ is 1.085. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.078. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.085TTM1.078+0.007
TTM1.078YOY1.174-0.096
TTM1.0785Y1.270-0.191
5Y1.27010Y1.293-0.024
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0851.099-0.014
TTM1.0781.149-0.071
YOY1.1741.109+0.065
5Y1.2701.101+0.169
10Y1.2931.055+0.238

1.3. Liquidity of Maxigen Biotech Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Maxigen Biotech Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 4.72 means the company has NT$4.72 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Maxigen Biotech Inc:

  • The MRQ is 4.716. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.676. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.716TTM4.676+0.040
TTM4.676YOY7.319-2.643
TTM4.6765Y4.857-0.180
5Y4.85710Y5.216-0.359
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7162.385+2.331
TTM4.6762.589+2.087
YOY7.3192.582+4.737
5Y4.8572.635+2.222
10Y5.2162.614+2.602
1.3.2. Quick Ratio

Measures if Maxigen Biotech Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 0.57 means the company can pay off NT$0.57 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Maxigen Biotech Inc:

  • The MRQ is 0.571. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.531. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.571TTM0.531+0.040
TTM0.531YOY1.078-0.547
TTM0.5315Y1.110-0.579
5Y1.11010Y1.479-0.369
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5711.165-0.594
TTM0.5311.172-0.641
YOY1.0781.283-0.205
5Y1.1101.392-0.282
10Y1.4791.477+0.002

1.4. Solvency of Maxigen Biotech Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Maxigen Biotech Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Maxigen Biotech Inc to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.09 means that Maxigen Biotech Inc assets are financed with 8.8% credit (debt) and the remaining percentage (100% - 8.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Maxigen Biotech Inc:

  • The MRQ is 0.088. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.107. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.088TTM0.107-0.019
TTM0.107YOY0.092+0.015
TTM0.1075Y0.139-0.032
5Y0.13910Y0.147-0.008
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0880.353-0.265
TTM0.1070.355-0.248
YOY0.0920.358-0.266
5Y0.1390.362-0.223
10Y0.1470.369-0.222
1.4.2. Debt to Equity Ratio

Measures if Maxigen Biotech Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 9.7% means that company has NT$0.10 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Maxigen Biotech Inc:

  • The MRQ is 0.097. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.121. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.097TTM0.121-0.024
TTM0.121YOY0.102+0.019
TTM0.1215Y0.172-0.051
5Y0.17210Y0.185-0.013
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0970.541-0.444
TTM0.1210.545-0.424
YOY0.1020.529-0.427
5Y0.1720.640-0.468
10Y0.1850.665-0.480

2. Market Valuation of Maxigen Biotech Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Maxigen Biotech Inc generates.

  • Above 15 is considered overpriced but always compare Maxigen Biotech Inc to the Medical Instruments & Supplies industry mean.
  • A PE ratio of 60.92 means the investor is paying NT$60.92 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Maxigen Biotech Inc:

  • The EOD is 57.522. Based on the earnings, the company is expensive. -2
  • The MRQ is 60.921. Based on the earnings, the company is expensive. -2
  • The TTM is 35.556. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD57.522MRQ60.921-3.398
MRQ60.921TTM35.556+25.365
TTM35.556YOY26.655+8.901
TTM35.5565Y39.713-4.157
5Y39.71310Y40.468-0.755
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD57.52217.039+40.483
MRQ60.92117.929+42.992
TTM35.55619.435+16.121
YOY26.65520.661+5.994
5Y39.71321.503+18.210
10Y40.46827.130+13.338
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Maxigen Biotech Inc:

  • The EOD is 20.976. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 22.216. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 52.975. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD20.976MRQ22.216-1.239
MRQ22.216TTM52.975-30.759
TTM52.975YOY16.130+36.845
TTM52.9755Y23.963+29.011
5Y23.96310Y23.163+0.800
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD20.97610.083+10.893
MRQ22.2169.744+12.472
TTM52.9751.298+51.677
YOY16.1304.667+11.463
5Y23.9634.114+19.849
10Y23.1630.108+23.055
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Maxigen Biotech Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 3.16 means the investor is paying NT$3.16 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Maxigen Biotech Inc:

  • The EOD is 2.986. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.162. Based on the equity, the company is fair priced.
  • The TTM is 3.717. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.986MRQ3.162-0.176
MRQ3.162TTM3.717-0.555
TTM3.717YOY3.255+0.462
TTM3.7175Y3.182+0.535
5Y3.18210Y3.139+0.044
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD2.9862.522+0.464
MRQ3.1622.733+0.429
TTM3.7172.706+1.011
YOY3.2553.220+0.035
5Y3.1823.824-0.642
10Y3.1394.219-1.080
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Maxigen Biotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0910.184-149%0.433-121%0.171-153%0.665-114%
Book Value Per Share--15.30515.153+1%13.813+11%11.871+29%11.647+31%
Current Ratio--4.7164.676+1%7.319-36%4.857-3%5.216-10%
Debt To Asset Ratio--0.0880.107-18%0.092-4%0.139-37%0.147-40%
Debt To Equity Ratio--0.0970.121-20%0.102-5%0.172-44%0.185-48%
Dividend Per Share----0%-0%0.305-100%0.302-100%
Eps--0.1990.466-57%0.428-54%0.298-33%0.283-30%
Free Cash Flow Per Share--0.5450.418+30%0.714-24%0.359+52%0.365+49%
Free Cash Flow To Equity Per Share--0.5450.418+30%0.711-23%0.281+94%0.285+91%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--6.989--------
Intrinsic Value_10Y_min--6.491--------
Intrinsic Value_1Y_max--1.722--------
Intrinsic Value_1Y_min--1.692--------
Intrinsic Value_3Y_max--4.395--------
Intrinsic Value_3Y_min--4.212--------
Intrinsic Value_5Y_max--6.130--------
Intrinsic Value_5Y_min--5.757--------
Market Cap4064288187.200-6%4304410246.4005002542900.000-14%3994252586.600+8%3445529214.280+25%3322268490.574+30%
Net Profit Margin--0.1190.263-55%0.227-48%0.185-36%0.180-34%
Operating Margin----0%0.179-100%0.150-100%0.145-100%
Operating Ratio--1.0851.078+1%1.174-8%1.270-15%1.293-16%
Pb Ratio2.986-6%3.1623.717-15%3.255-3%3.182-1%3.139+1%
Pe Ratio57.522-6%60.92135.556+71%26.655+129%39.713+53%40.468+51%
Price Per Share45.700-6%48.40056.250-14%44.913+8%38.743+25%37.357+30%
Price To Free Cash Flow Ratio20.976-6%22.21652.975-58%16.130+38%23.963-7%23.163-4%
Price To Total Gains Ratio-504.504+6%-534.311-135.436-75%111.263-580%44.354-1305%42.927-1345%
Quick Ratio--0.5710.531+8%1.078-47%1.110-49%1.479-61%
Return On Assets--0.0120.027-57%0.026-54%0.020-42%0.020-40%
Return On Equity--0.0130.031-58%0.028-54%0.024-45%0.023-44%
Total Gains Per Share---0.0910.184-149%0.433-121%0.477-119%0.967-109%
Usd Book Value--42602523.90042179175.750+1%38449522.525+11%33045176.885+29%32421106.122+31%
Usd Book Value Change Per Share---0.0030.006-149%0.014-121%0.005-153%0.021-114%
Usd Book Value Per Share--0.4790.474+1%0.432+11%0.372+29%0.365+31%
Usd Dividend Per Share----0%-0%0.010-100%0.009-100%
Usd Eps--0.0060.015-57%0.013-54%0.009-33%0.009-30%
Usd Free Cash Flow--1516140.7001164039.175+30%1986736.200-24%999313.535+52%1016607.670+49%
Usd Free Cash Flow Per Share--0.0170.013+30%0.022-24%0.011+52%0.011+49%
Usd Free Cash Flow To Equity Per Share--0.0170.013+30%0.022-23%0.009+94%0.009+91%
Usd Market Cap127212220.259-6%134728040.712156579592.770-14%125020105.961+8%107845064.407+25%103987003.755+30%
Usd Price Per Share1.430-6%1.5151.761-14%1.406+8%1.213+25%1.169+30%
Usd Profit--552883.2001297604.100-57%1090836.300-49%808042.365-32%768785.157-28%
Usd Revenue--4655624.6004868049.875-4%4729672.575-2%4144764.780+12%4041311.748+15%
Usd Total Gains Per Share---0.0030.006-149%0.014-121%0.015-119%0.030-109%
 EOD+5 -3MRQTTM+15 -17YOY+10 -235Y+17 -1810Y+16 -19

3.2. Fundamental Score

Let's check the fundamental score of Maxigen Biotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1557.522
Price to Book Ratio (EOD)Between0-12.986
Net Profit Margin (MRQ)Greater than00.119
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.571
Current Ratio (MRQ)Greater than14.716
Debt to Asset Ratio (MRQ)Less than10.088
Debt to Equity Ratio (MRQ)Less than10.097
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.012
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Maxigen Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.436
Ma 20Greater thanMa 5045.490
Ma 50Greater thanMa 10045.922
Ma 100Greater thanMa 20046.953
OpenGreater thanClose46.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets1,492,986
Total Liabilities131,883
Total Stockholder Equity1,361,103
 As reported
Total Liabilities 131,883
Total Stockholder Equity+ 1,361,103
Total Assets = 1,492,986

Assets

Total Assets1,492,986
Total Current Assets619,563
Long-term Assets873,423
Total Current Assets
Cash And Cash Equivalents 431,082
Short-term Investments 1,500
Net Receivables 73,459
Inventory 85,185
Other Current Assets 77
Total Current Assets  (as reported)619,563
Total Current Assets  (calculated)591,303
+/- 28,260
Long-term Assets
Property Plant Equipment 424,178
Long-term Assets Other 10,126
Long-term Assets  (as reported)873,423
Long-term Assets  (calculated)434,304
+/- 439,119

Liabilities & Shareholders' Equity

Total Current Liabilities131,373
Long-term Liabilities510
Total Stockholder Equity1,361,103
Total Current Liabilities
Short Long Term Debt 50
Accounts payable 17,119
Other Current Liabilities 773
Total Current Liabilities  (as reported)131,373
Total Current Liabilities  (calculated)17,942
+/- 113,431
Long-term Liabilities
Long-term Liabilities Other 19
Long-term Liabilities  (as reported)510
Long-term Liabilities  (calculated)19
+/- 491
Total Stockholder Equity
Retained Earnings 199,447
Total Stockholder Equity (as reported)1,361,103
Total Stockholder Equity (calculated)199,447
+/- 1,161,656
Other
Capital Stock890,298
Common Stock Shares Outstanding 88,934
Net Invested Capital 1,361,153
Net Working Capital 488,190
Property Plant and Equipment Gross 424,178



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
> Total Assets 
1,126,534
1,121,350
1,135,457
1,154,402
1,196,173
1,155,679
1,185,486
969,277
975,966
930,842
956,470
977,366
1,016,271
1,241,498
1,265,184
1,274,517
1,316,744
1,377,395
1,447,723
1,492,249
1,511,991
1,542,851
1,492,986
1,492,9861,542,8511,511,9911,492,2491,447,7231,377,3951,316,7441,274,5171,265,1841,241,4981,016,271977,366956,470930,842975,966969,2771,185,4861,155,6791,196,1731,154,4021,135,4571,121,3501,126,534
   > Total Current Assets 
615,843
585,086
599,525
600,914
644,365
608,242
640,152
425,840
440,306
402,982
432,058
459,893
501,468
730,010
783,553
801,969
863,373
930,728
993,246
1,047,118
622,543
644,357
619,563
619,563644,357622,5431,047,118993,246930,728863,373801,969783,553730,010501,468459,893432,058402,982440,306425,840640,152608,242644,365600,914599,525585,086615,843
       Cash And Cash Equivalents 
182,308
165,353
184,844
216,802
211,534
172,393
267,643
162,319
141,635
148,981
209,762
201,591
208,885
446,119
513,305
568,620
624,944
712,132
790,948
831,736
402,999
419,925
431,082
431,082419,925402,999831,736790,948712,132624,944568,620513,305446,119208,885201,591209,762148,981141,635162,319267,643172,393211,534216,802184,844165,353182,308
       Short-term Investments 
214,622
222,613
197,067
208,942
201,720
215,821
165,049
46,089
49,048
12,876
13,135
41,571
40,791
26,840
26,872
27,831
29,677
14,919
10,316
10,362
10,064
1,500
1,500
1,5001,50010,06410,36210,31614,91929,67727,83126,87226,84040,79141,57113,13512,87649,04846,089165,049215,821201,720208,942197,067222,613214,622
       Net Receivables 
106,789
101,729
86,556
59,117
103,368
100,492
106,216
104,449
133,339
130,132
100,259
108,398
129,295
138,314
114,710
104,634
117,721
111,392
100,272
66,474
87,793
90,455
73,459
73,45990,45587,79366,474100,272111,392117,721104,634114,710138,314129,295108,398100,259130,132133,339104,449106,216100,492103,36859,11786,556101,729106,789
       Inventory 
80,337
76,272
82,618
75,174
80,970
73,847
88,115
97,022
94,999
87,145
86,984
85,001
97,886
94,854
80,634
63,870
67,800
74,671
75,410
75,551
86,425
97,071
85,185
85,18597,07186,42575,55175,41074,67167,80063,87080,63494,85497,88685,00186,98487,14594,99997,02288,11573,84780,97075,17482,61876,27280,337
   > Long-term Assets 
0
0
0
553,488
551,808
547,437
545,334
543,437
535,660
527,860
524,412
517,473
514,803
511,488
481,631
472,548
453,371
446,667
454,477
445,131
889,448
898,494
873,423
873,423898,494889,448445,131454,477446,667453,371472,548481,631511,488514,803517,473524,412527,860535,660543,437545,334547,437551,808553,488000
       Property Plant Equipment 
496,064
495,180
494,029
510,580
508,622
504,506
502,090
500,599
493,010
485,328
481,517
474,552
472,054
469,344
465,453
0
439,028
432,407
434,622
434,960
430,107
425,732
424,178
424,178425,732430,107434,960434,622432,407439,0280465,453469,344472,054474,552481,517485,328493,010500,599502,090504,506508,622510,580494,029495,180496,064
       Intangible Assets 
2,285
2,121
2,585
2,386
2,709
2,507
2,236
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,2362,5072,7092,3862,5852,1212,285
       Long-term Assets Other 
0
0
0
26,501
26,501
26,501
26,501
26,501
26,501
26,501
27,891
27,891
27,891
31,266
5,111
3,626
3,025
3,075
6,674
4,649
4,329
10,143
10,126
10,12610,1434,3294,6496,6743,0753,0253,6265,11131,26627,89127,89127,89126,50126,50126,50126,50126,50126,50126,501000
> Total Liabilities 
309,107
286,204
79,343
304,688
371,923
311,802
334,169
107,727
148,003
90,758
96,243
95,491
112,969
116,233
123,466
108,854
113,756
128,026
152,066
148,482
195,710
173,692
131,883
131,883173,692195,710148,482152,066128,026113,756108,854123,466116,233112,96995,49196,24390,758148,003107,727334,169311,802371,923304,68879,343286,204309,107
   > Total Current Liabilities 
84,334
73,415
79,254
290,519
358,401
298,935
321,950
96,157
137,084
80,445
86,584
86,418
104,386
108,240
116,068
102,052
113,736
128,007
151,500
147,901
195,212
173,194
131,373
131,373173,194195,212147,901151,500128,007113,736102,052116,068108,240104,38686,41886,58480,445137,08496,157321,950298,935358,401290,51979,25473,41584,334
       Short-term Debt 
1,650
0
0
0
0
214,445
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000214,44500001,650
       Short Long Term Debt 
1,650
0
0
0
0
214,445
0
0
0
0
0
90
0
18
100
0
0
0
0
0
0
50
50
50500000001001809000000214,44500001,650
       Accounts payable 
30,369
32,044
30,995
29,841
38,786
23,548
33,969
37,424
36,866
37,512
33,001
30,860
43,834
50,670
40,153
22,727
40,467
40,265
35,939
38,691
57,701
30,763
17,119
17,11930,76357,70138,69135,93940,26540,46722,72740,15350,67043,83430,86033,00137,51236,86637,42433,96923,54838,78629,84130,99532,04430,369
       Other Current Liabilities 
20,324
3,987
4,403
218,210
218,962
219,867
22,631
25,375
67,648
9,259
14,452
22,260
27,322
26,435
33,203
41,996
31,468
40,351
60,212
542
876
839
773
77383987654260,21240,35131,46841,99633,20326,43527,32222,26014,4529,25967,64825,37522,631219,867218,962218,2104,4033,98720,324
   > Long-term Liabilities 
0
0
0
14,169
13,522
12,867
12,219
11,570
10,919
10,313
9,659
9,073
8,583
7,993
7,398
6,802
20
19
566
581
498
498
510
51049849858156619206,8027,3987,9938,5839,0739,65910,31310,91911,57012,21912,86713,52214,169000
       Capital Lease Obligations 
0
0
0
16,619
15,981
15,328
14,691
14,051
13,409
12,773
12,133
11,483
10,830
10,225
9,640
9,054
0
0
0
0
0
0
0
00000009,0549,64010,22510,83011,48312,13312,77313,40914,05114,69115,32815,98116,619000
       Long-term Liabilities Other 
0
0
0
89
89
89
89
89
89
89
19
19
119
120
120
120
20
19
19
19
19
19
19
19191919191920120120120119191989898989898989000
> Total Stockholder Equity
810,626
828,345
836,178
849,714
824,250
843,877
851,317
861,550
827,963
840,084
860,227
881,875
903,302
1,125,265
1,141,718
1,165,663
1,202,988
1,249,369
1,295,657
1,343,767
1,316,281
1,369,159
1,361,103
1,361,1031,369,1591,316,2811,343,7671,295,6571,249,3691,202,9881,165,6631,141,7181,125,265903,302881,875860,227840,084827,963861,550851,317843,877824,250849,714836,178828,345810,626
   Common Stock
708,470
708,470
708,470
708,470
694,650
694,650
694,650
694,650
694,650
694,650
694,650
694,650
694,650
769,992
769,992
0
769,992
769,992
846,991
0
0
0
0
0000846,991769,992769,9920769,992769,992694,650694,650694,650694,650694,650694,650694,650694,650694,650708,470708,470708,470708,470
   Retained Earnings 
36,706
54,377
62,226
64,317
33,155
52,646
70,417
80,603
46,954
59,153
79,381
101,001
122,391
97,003
110,295
107,121
85,065
125,895
169,801
181,913
144,781
185,095
199,447
199,447185,095144,781181,913169,801125,89585,065107,121110,29597,003122,391101,00179,38159,15346,95480,60370,41752,64633,15564,31762,22654,37736,706
   Accumulated Other Comprehensive Income 00000000000000000000000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue622,115
Cost of Revenue-198,021
Gross Profit424,094424,094
 
Operating Income (+$)
Gross Profit424,094
Operating Expense-472,066
Operating Income150,049-47,972
 
Operating Expense (+$)
Research Development68,595
Selling General Administrative205,450
Selling And Marketing Expenses0
Operating Expense472,066274,045
 
Net Interest Income (+$)
Interest Income12,307
Interest Expense-0
Other Finance Cost-0
Net Interest Income12,307
 
Pretax Income (+$)
Operating Income150,049
Net Interest Income12,307
Other Non-Operating Income Expenses0
Income Before Tax (EBT)193,142150,049
EBIT - interestExpense = 0
165,828
165,828
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0193,142
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax193,142
Tax Provision-27,314
Net Income From Continuing Ops165,828165,828
Net Income165,828
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-12,307
 

Technical Analysis of Maxigen Biotech Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Maxigen Biotech Inc. The general trend of Maxigen Biotech Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Maxigen Biotech Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Maxigen Biotech Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 48.80 < 49.45 < 50.00.

The bearish price targets are: 45.65 > 44.40 > 44.30.

Tweet this
Maxigen Biotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Maxigen Biotech Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Maxigen Biotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Maxigen Biotech Inc. The current macd is -0.25099577.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Maxigen Biotech Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Maxigen Biotech Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Maxigen Biotech Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Maxigen Biotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartMaxigen Biotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Maxigen Biotech Inc. The current adx is 21.21.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Maxigen Biotech Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Maxigen Biotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Maxigen Biotech Inc. The current sar is 44.51.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Maxigen Biotech Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Maxigen Biotech Inc. The current rsi is 49.44. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Maxigen Biotech Inc Daily Relative Strength Index (RSI) ChartMaxigen Biotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Maxigen Biotech Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Maxigen Biotech Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Maxigen Biotech Inc Daily Stochastic Oscillator ChartMaxigen Biotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Maxigen Biotech Inc. The current cci is 46.20.

Maxigen Biotech Inc Daily Commodity Channel Index (CCI) ChartMaxigen Biotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Maxigen Biotech Inc. The current cmo is 3.67281177.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Maxigen Biotech Inc Daily Chande Momentum Oscillator (CMO) ChartMaxigen Biotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Maxigen Biotech Inc. The current willr is -35.13513514.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Maxigen Biotech Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Maxigen Biotech Inc Daily Williams %R ChartMaxigen Biotech Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Maxigen Biotech Inc.

Maxigen Biotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Maxigen Biotech Inc. The current atr is 0.81265352.

Maxigen Biotech Inc Daily Average True Range (ATR) ChartMaxigen Biotech Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Maxigen Biotech Inc. The current obv is 40,511,133.

Maxigen Biotech Inc Daily On-Balance Volume (OBV) ChartMaxigen Biotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Maxigen Biotech Inc. The current mfi is 60.11.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Maxigen Biotech Inc Daily Money Flow Index (MFI) ChartMaxigen Biotech Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Maxigen Biotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-02STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.

6.3. Candlestick Patterns

Maxigen Biotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Maxigen Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.436
Ma 20Greater thanMa 5045.490
Ma 50Greater thanMa 10045.922
Ma 100Greater thanMa 20046.953
OpenGreater thanClose46.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Maxigen Biotech Inc with someone you think should read this too:
  • Are you bullish or bearish on Maxigen Biotech Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Maxigen Biotech Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Maxigen Biotech Inc

I send you an email if I find something interesting about Maxigen Biotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Maxigen Biotech Inc.

Receive notifications about Maxigen Biotech Inc in your mailbox!